#BEGIN_DRUGCARD DB04181

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H19N5O7S2

# Chemical_IUPAC_Name:
(2S)-2-[(1R)-1-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-oxoethyl]-5-(2-methoxy-2-oxoethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cefotaxime Group

# HET_ID:
CEF

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H19N5O7S2/c1-27-10(23)3-7-5-29-14(20-11(7)15(25)26)8(4-22)18-13(24)12(21-28-2)9-6-30-16(17)19-9/h4,6,8,14,20H,3,5H2,1-2H3,(H2,17,19)(H,18,24)(H,25,26)/b21-12+/t8-,14+/m1/s1

# InChI_Key:
InChIKey=MXZSNCHJXJJUNP-VTSIPFNDSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4181

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
457.481

# Molecular_Weight_Mono:
457.072589367

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1IYO

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.17

# Predicted_LogS:
-3.7

# Predicted_Water_Solubility:
8.56e-02 g/l

# Primary_Accession_No:
DB04181

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936913

# PubChem_Substance_ID:
46505113

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00885

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CO\N=C(\C(=O)N[C@H](C=O)[C@H]1NC(C(O)=O)=C(CC(=O)OC)CS1)C1=CSC(N)=N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:03 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D37830

# Drug_Target_1_GenBank_ID_Protein:
1037162

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
bla

# Drug_Target_1_Gene_Sequence:
>876 bp
ATGATGACTCAGAGCATTCGCCGCTCAATGTTAACGGTGATGGCGACGCTACCCCTGCTA
TTTAGCAGCGCAACGCTGCATGCGCAGGCGAACAGCGTGCAACAGCAGCTGGAAGCCCTG
GAGAAAAGTTCGGGAGGTCGGCTTGGCGTTGCGCTGATTAACACCGCCGATAATTCGCAG
ATTCTCTACCGTGCCGATGAACGTTTTGCGATGTGCAGTACCAGTAAGGTGATGGCGGCC
GCGGCGGTGCTTAAACAGAGCGAGAGCGATAAGCACCTGCTAAATCAGCGCGTTGAAATC
AAGAAGAGCGACCTGGTTAACTACAATCCCATTGCGGAGAAACACGTTAACGGCACGATG
ACGCTGGCTGAGCTTGGCGCAGCGGCGCTGCAGTATAGCGACAATACTGCCATGAATAAG
CTGATTGCCCATCTGGGTGGTCCCGATAAAGTGACGGCGTTTGCTCGCTCGTTGGGTGAT
GAGACCTTCCGTCTGGACAGAACCGAGCCCACGCTCAATACCGCCATTCCAGGCGACCCG
CGTGATACCACCACGCCGCTCGCGATGGCGCAGACCCTGAAAAATCTGACGCTGGGTAAA
GCGCTGGCGGAAACTCAGCGGGCACAGTTGGTGACGTGGCTTAAGGGCAATACTACCGGT
AGCGCGAGCATTCGGGCGGGTCTGCCGAAATCATGGGTAGTGGGCGATAAAACCGGCAGC
GGAGATTATGGCACCACCAACGATATCGCGGTTATCTGGCCGGAAAACCACGCACCGCTG
GTTCTGGTGACCTACTTTACCCAACCGGAGCAGAAGGCGGAAAGGCGTCGGGATATTCTG
GCTGCGGCGGCGAAAATCGTAACCCACGGTTTCTGA

# Drug_Target_1_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_1_General_References:
8619581	Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75.
9925786	Ibuka A, Taguchi A, Ishiguro M, Fushinobu S, Ishii Y, Kamitori S, Okuyama K, Yamaguchi K, Konno M, Matsuzawa H: Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution. J Mol Biol. 1999 Feb 5;285(5):2079-87.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3195

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
31447

# Drug_Target_1_Name:
Beta-lactamase Toho-1

# Drug_Target_1_Number_of_Residues:
291

# Drug_Target_1_PDB_ID:
1IYS

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_1_Protein_Sequence:
>Beta-lactamase Toho-1 precursor
MMTQSIRRSMLTVMATLPLLFSSATLHAQANSVQQQLEALEKSSGGRLGVALINTADNSQ
ILYRADERFAMCSTSKVMAAAAVLKQSESDKHLLNQRVEIKKSDLVNYNPIAEKHVNGTM
TLAELGAAALQYSDNTAMNKLIAHLGGPDKVTAFARSLGDETFRLDRTEPTLNTAIPGDP
RDTTTPLAMAQTLKNLTLGKALAETQRAQLVTWLKGNTTGSASIRAGLPKSWVVGDKTGS
GDYGTTNDIAVIWPENHAPLVLVTYFTQPEQKAERRRDILAAAAKIVTHGF

# Drug_Target_1_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_1_Signals:
1-29

# Drug_Target_1_Specific_Function:
Has strong cefotaxime-hydrolyzing activity

# Drug_Target_1_SwissProt_ID:
Q47066

# Drug_Target_1_SwissProt_Name:
BLT1_ECOLX

# Drug_Target_1_Synonyms:
Beta-lactamase Toho-1 precursor
EC 3.5.2.6

# Drug_Target_1_Theoretical_pI:
9.60

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04181
